This proposal seeks to develop an interdisciplinary Nanomedicine Center at the University of Nebraska Medical Center. We have assembled a team of scientists with specific expertise in nanomedicine, drug delivery, therapeutics and diagnostics. These will now be joined by biochemists, pharmacologists, immunologists and neuroscientists. All will work, with singular focus, to develop the means to best use devices of nanoscale size to improve outcomes for cancer, neurodegenerative and cardiovascular diseases. Such approaches will deliver drugs to focal areas of central nervous system disease or directly to tumors. Parallel studies seek nanotechnologies to improve diagnostic measures and disease monitoring. The anticipated outcome is to maximize clinical benefits and limit untoward side effects. Nanotechnology is amongst the most rapidly developing approaches available towards for drug and gene delivery. Indeed, the National Institutes of Health (NIH) have identified the need in developing the field of Nanomedicine as an integral component of its strategic plan. The challenges in realizing these goals require the formation of multidisciplinary research centers that include broad expertise in material, pharmaceutical and biological sciences driven by innovative research. This is the foundation for the Nebraska Center for Nanomedicine (NCN). The long-term goals are to build upon and integrate already strong areas of research in cancer biology, neurodegenerative disorders, molecular imaging (magnetic resonance and single photon emission computed tomography) with material and pharmaceutical sciences (nanomaterials, polymers, drug delivery, and gene delivery). The envisioned cross-disciplinary expertise could be joined between traditional biomedical research and material sciences through the NCN.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
8P20GM103480-05
Application #
8299056
Study Section
Special Emphasis Panel (ZRR1-RI-2 (01))
Program Officer
Canto, Maria Teresa
Project Start
2008-09-26
Project End
2013-09-14
Budget Start
2012-07-01
Budget End
2013-09-14
Support Year
5
Fiscal Year
2012
Total Cost
$2,020,247
Indirect Cost
$659,811
Name
University of Nebraska Medical Center
Department
Other Basic Sciences
Type
Schools of Pharmacy
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Macha, M A; Rachagani, S; Pai, P et al. (2015) MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway. Oncogene 34:1698-708
Macha, Muzafar A; Seshacharyulu, Parthasarathy; Krishn, Shiv Ram et al. (2014) MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des 20:5287-97
Gutti, Tanuja L; Knibbe, Jaclyn S; Makarov, Edward et al. (2014) Human hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice. Am J Pathol 184:101-9
Yi, Xiang; Manickam, Devika S; Brynskikh, Anna et al. (2014) Agile delivery of protein therapeutics to CNS. J Control Release 190:637-63
Alakhova, Daria Y; Kabanov, Alexander V (2014) Pluronics and MDR reversal: an update. Mol Pharm 11:2566-78
Savalia, Krupa; Manickam, Devika S; Rosenbaugh, Erin G et al. (2014) Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration. Free Radic Biol Med 73:299-307
Shi, Wen; Ogbomo, Sunny M; Wagh, Nilesh K et al. (2014) The influence of linker length on the properties of cathepsin S cleavable (177)Lu-labeled HPMA copolymers for pancreatic cancer imaging. Biomaterials 35:5760-70
Gupta, Suprit; Batra, Surinder; Jain, Maneesh (2014) Antibody labeling with radioiodine and radiometals. Methods Mol Biol 1141:147-57
Nukolova, Natalia V; Oberoi, Hardeep S; Zhao, Yi et al. (2013) LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer. Mol Pharm 10:3913-21
Zhou, Zhengyuan; Wagh, Nilesh K; Ogbomo, Sunny M et al. (2013) Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. J Nucl Med 54:1605-12

Showing the most recent 10 out of 16 publications